はじめての方へショーケース価格
  1. 米国企業
  2. BIOGEN INC.

BIOGEN INC.BIIB

時価総額
$335.2億
PER
27.5倍
サマリーテーブルに戻る
損益計算書バランスシートキャッシュフロー
2010年
12月31日		2011年
12月31日		2012年
12月31日		2013年
12月31日		2014年
12月31日		2015年
12月31日		2016年
12月31日		2017年
12月31日		2018年
12月31日		2019年
12月31日		2020年
12月31日		2021年
12月31日		2022年
12月31日		2023年
12月31日
Net income8991,2671,3801,8622,9423,5933,6962,6704,4745,8894,0611,7282,9621,162
Depreciation and amortization---5326886006831,0811,017681457488518495
Impairment of intangible assets----------210629120-
Inventory Write-down122525--------168336124
Research and Development in Process271------120113-7518--
Amortization of inventory step-up-------------32
Share-based compensation168113119136155161155128158182198239254264
Contingent consideration---139-30-15-6312648651209-
Share-based compensation168113119136155161155128158182198239254264
(Gain)/loss on divestiture of Hillerød, Denmark manufacturing operations----------5593---
Contingent consideration---139-30-15-6312648651209-
Deferred income taxes-81154-117-245-308-146-1759210867149-427-169-306
(Gain) loss on strategic investments----------682-827-266-277
(Gain) loss on equity method investment---5-17-15-12----793353-
Gain on sale of equity interest in Samsung Bioepis------------1,505-
Gain on sale of building------------504-
Other---322850-82-91-16269-69-131-202-208-148
Accounts receivable9973-4127512-29241436205-69-3-325203-61
Due from anti-CD20 therapeutic programs----163131-14232-663-177-1195
Inventory559140244186174166955219316462320131
Increase (Decrease) in Accrued Liabilities1313427328424474570-227466240154-95-113-202
Income tax assets and liabilities------410-2331,30432216-67231-142-299
Increase (Decrease) in Other Operating Liabilities18-3634319959470-2-16-43-137-144-92-74
Net cash flow provided by (used in) operating activities1,6251,7281,8802,3452,9423,7164,5224,5516,1887,0794,2303,6401,3841,547
Purchases of property, plant and equipment173208255246288643616867771515425258240277
Proceeds from sales and maturities of marketable securities---5,1902,7194,0637,3795,5669,1746,0077,2993,4053,6717,381
Purchases of marketable securities----------6,3983,8093,4495,141
Proceeds from sale of equity interest in Samsung Bioepis------------990788
Proceeds from sale of building725-15-199---744---6,926
Proceeds from sale of building-------------583-
Proceeds from sale of equity interest in Samsung Bioepis------------990788
Sangamo Therapeutics, Inc. Agreement----------142---
Denali Therapeutics----------424---
Sage Therapeutics----------441---
Proceeds from sale of building-------------583-
Proceeds from Sale of Property, Plant, and Equipment-2-------924-28--
Acquired in-process research and development-------120113-7518--
Acquisitions of intangible assets-4473,263--11297531555219334
Proceeds from sales of strategic investments-41--------7594-120
Other----716602311-0-2727-13-2411
Net cash flow provided by (used in) investing activities345-1,650-950-1,605-1,543-4,554-2,485-2,963-2,046471-609-5641,577-4,101
Purchase of treasury stock2,0784989854008875,0001,0001,3654,3535,8686,6791,800750-
Payments related to issuance of stock for share-based compensation arrangements, net-------52--1244
Repayments of borrowings and premiums paid-----------1701,002810
Proceeds from borrowings----------2,967--997
Repayments of borrowings---4523235613-1,500---
Proceeds from (Payments to) Noncontrolling Interests------------941212
Proceeds from (Payments to) Noncontrolling Interests------------941212
Other---7-4-18-74-3-9-19415-21-6-6
Other---7-4-18-74-3-9-19415-21-6-6
Net cash flow provided by (used in) financing activities-1,785-320-877-717-756986-988-2,380-4,472-5,860-5,273-2,086-1,747149
Net cash flow provided by (used in) financing activities-1,785-320-877-717-756986-988-2,380-4,472-5,860-5,273-2,086-1,747149
Net increase (decrease) in cash and cash equivalents-----------1,6519901,214-2,404
Effect of exchange rate changes on cash and cash equivalents----------69-60-5635
Net income8991,2671,3801,8622,9423,5933,6962,6704,4745,8894,0611,7282,9621,162
Depreciation and amortization---5326886006831,0811,017681457488518495
Impairment of intangible assets----------210629120-
Inventory Write-down122525--------168336124
Research and Development in Process271------120113-7518--
Amortization of inventory step-up-------------32
Share-based compensation168113119136155161155128158182198239254264
Contingent consideration---139-30-15-6312648651209-
Share-based compensation168113119136155161155128158182198239254264
(Gain)/loss on divestiture of Hillerød, Denmark manufacturing operations----------5593---
Contingent consideration---139-30-15-6312648651209-
Deferred income taxes-81154-117-245-308-146-1759210867149-427-169-306
(Gain) loss on strategic investments----------682-827-266-277
(Gain) loss on equity method investment---5-17-15-12----793353-
Gain on sale of equity interest in Samsung Bioepis------------1,505-
Gain on sale of building------------504-
Other---322850-82-91-16269-69-131-202-208-148
Accounts receivable9973-4127512-29241436205-69-3-325203-61
Due from anti-CD20 therapeutic programs----163131-14232-663-177-1195
Inventory559140244186174166955219316462320131
Increase (Decrease) in Accrued Liabilities1313427328424474570-227466240154-95-113-202
Income tax assets and liabilities------410-2331,30432216-67231-142-299
Increase (Decrease) in Other Operating Liabilities18-3634319959470-2-16-43-137-144-92-74
Net cash flow provided by (used in) operating activities1,6251,7281,8802,3452,9423,7164,5224,5516,1887,0794,2303,6401,3841,547
Purchases of property, plant and equipment173208255246288643616867771515425258240277
Proceeds from sales and maturities of marketable securities---5,1902,7194,0637,3795,5669,1746,0077,2993,4053,6717,381
Purchases of marketable securities----------6,3983,8093,4495,141
Proceeds from sale of equity interest in Samsung Bioepis------------990788
Proceeds from sale of building725-15-199---744---6,926
Proceeds from sale of building-------------583-
Proceeds from sale of equity interest in Samsung Bioepis------------990788
Sangamo Therapeutics, Inc. Agreement----------142---
Denali Therapeutics----------424---
Sage Therapeutics----------441---
Proceeds from sale of building-------------583-
Proceeds from Sale of Property, Plant, and Equipment-2-------924-28--
Acquired in-process research and development-------120113-7518--
Acquisitions of intangible assets-4473,263--11297531555219334
Proceeds from sales of strategic investments-41--------7594-120
Other----716602311-0-2727-13-2411
Net cash flow provided by (used in) investing activities345-1,650-950-1,605-1,543-4,554-2,485-2,963-2,046471-609-5641,577-4,101
Purchase of treasury stock2,0784989854008875,0001,0001,3654,3535,8686,6791,800750-
Payments related to issuance of stock for share-based compensation arrangements, net-------52--1244
Repayments of borrowings and premiums paid-----------1701,002810
Proceeds from borrowings----------2,967--997
Repayments of borrowings---4523235613-1,500---
Proceeds from (Payments to) Noncontrolling Interests------------941212
Proceeds from (Payments to) Noncontrolling Interests------------941212
Other---7-4-18-74-3-9-19415-21-6-6
Other---7-4-18-74-3-9-19415-21-6-6
Net cash flow provided by (used in) financing activities-1,785-320-877-717-756986-988-2,380-4,472-5,860-5,273-2,086-1,747149
Net cash flow provided by (used in) financing activities-1,785-320-877-717-756986-988-2,380-4,472-5,860-5,273-2,086-1,747149
Net increase (decrease) in cash and cash equivalents-----------1,6519901,214-2,404
Effect of exchange rate changes on cash and cash equivalents----------69-60-5635